2. Antibody-drug Conjugate/ADC Related Protein Tyrosine Kinase/RTK Cell Cycle/DNA Damage Metabolic Enzyme/Protease Vitamin D Related/Nuclear Receptor
  3. ADC Antibody RET PERK ROR
  4. Cofetuzumab

Cofetuzumab  (Synonyms: PF-06523435; hu24)

Cat. No.: HY-P99828 Purity: 99.31%
COA
SDS
Technical Support

Cofetuzumab (PF-06523435) is a humanized IgG1-κ monoclonal antibody targeting PTK7. The expression system of Cofetuzumab is typically CHO (Chinese hamster ovary) cells. Cofetuzumab downregulates PTK7 expression, modulates its downstream signaling pathways, and inhibits tumor sphere formation of ovarian cancer cells. Cofetuzumab can be used to synthesize the ADC molecule Cofetuzumab pelidotin (HY-P99829). Cofetuzumab is applicable to the research of tumors such as ovarian cancer.

For research use only. We do not sell to patients.

CAS No. : 1869928-62-0

Size Price Stock Quantity
Free Sample (100 μg)   Apply Now  
1 mg In-stock
5 mg In-stock
10 mg In-stock
25 mg In-stock
50 mg In-stock
100 mg   Get quote  
200 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Cofetuzumab Featured Recommendations:

Cofetuzumab Related Antibodies

Top Publications Citing Use of Products

View All ROR Isoform Specific Products:

View All Isoforms
RORγ RORα RORβ

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Cofetuzumab (PF-06523435) is a humanized IgG1-κ monoclonal antibody targeting PTK7. The expression system of Cofetuzumab is typically CHO (Chinese hamster ovary) cells. Cofetuzumab downregulates PTK7 expression, modulates its downstream signaling pathways, and inhibits tumor sphere formation of ovarian cancer cells. Cofetuzumab can be used to synthesize the ADC molecule Cofetuzumab pelidotin (HY-P99829). Cofetuzumab is applicable to the research of tumors such as ovarian cancer[1].

Isotype

Human IgG1 kappa
Recommend Isotype Controls
Species Reactivity

Human
IC50 & Target

PTK7/CCK4
In Vitro

Cofetuzumab (10 μg/mL; 48 h) upregulates pERK1/2 in FIMM-PDC1-PDC3, and simultaneously upregulates ROR1 expression in FIMM-PDC3 with high PTK7 expression[1].
Cofetuzumab (10 μg/mL; 48 h) downregulates the expression level of SNCG protein in Kuramochi cells and FIMM-PDC1 cells[1].
Cofetuzumab (20 μg/mL; 5 days) inhibits tumor sphere formation and induces more dispersed structures in JHOS2, Kuramochi, FIMM-PDC3 and FIMM-PDC7 cells[1].
Cofetuzumab (10 μg/mL; 24 h) exerts synergistic cytotoxicity with Prexasertib (HY-18174) and Paclitaxel (HY-B0015) in FIMM-PDC3 cells[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cofetuzumab Related Antibodies

Western Blot Analysis[1]

Cell Line: Kuramochi (high-grade serous ovarian cancer cell line), FIMM-PDC1 (high-grade serous ovarian cancer patient-derived cell culture)
Concentration: 10 μg/mL
Incubation Time: 48 h
Result: Downregulated synuclein-γ (SNCG) protein levels in both cell models.
Gene ID

5754  [NCBI]

Accession

Q13308-1
Application

ELISA, FACS, Functional assay
Conjugated

Unconjugated
Reconsititution

The product can be reconstituted/diluted with sterile PBS or saline.
Molecular Weight

146.7 kDa

CAS No.
Appearance

Liquid

Color

Colorless to light yellow

SMILES

[Cofetuzumab]
Shipping

Shipping with dry ice.
Formulation

Please refer to the lot-specific COA for specific buffer information.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Format
  • Human IgG1 kappa
Biological Activity
  • Immobilized Human PTK7/CCK4, Fc Tag can bind Cofetuzumab. The EC50 for this effect is 21.74 ng/mL.
  • Flow Cytometry analysis of Hela cells labelling PTK7/CCK4 (red) with Cofetuzumab (anti-PTK7/CCK4) (HY-P99828). Goat Anti-Human IgG (Alexa Fluor 488) (HY-P83776) at a dilution of 1/1000 was used as the secondary antibody. Blue-Human IgG1 kappa (HY-P99001). Black-Unlabelled control, cells without incubation with primary antibody.
Purity & Documentation

Purity: 99.31%

SDS (251 KB)

COA (232 KB) SDS-PAGE (72 KB) SEC-HPLC (131 KB)

Inhibitory Antibodies User Guide (603 KB)
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Cofetuzumab Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Cofetuzumab1869928-62-0PF-06523435 hu24PF06523435PF 06523435hu24hu 24hu-24ADC AntibodyRETPERKRORProtein kinase R-like endoplasmic reticulum kinasePKR-like endoplasmic reticulum kinaseRAR-related orphan receptorSNCGPTK7ovarian cancerspheroid formationpatient-derived cell culturesovarian cancer cellspERK/pAKTROR1Kuramochi cellsJHOS2 cellsInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Cofetuzumab
Cat. No.:
HY-P99828
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (251 KB) Français - FR (251 KB) Deutsch - DE (251 KB) Norwegian - NO (251 KB) Español - ES (251 KB) Swedish - SV (251 KB) Italian - IT (251 KB) Korean - KR (251 KB) Portuguese - PT (251 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.